Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB-1005 · 1 trial · 1 indication
Number and proportion of participants with at least one adverse event
| Arm | Type | Description |
|---|---|---|
| AB-1005 infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AB-1005 | DRUG | Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose |
Inclusion Criteria: * Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent * Diagnosed with Parkinson's disease in the past 4-10 years (inclusive) and currently meeting all the following criteria: 1. Presence of bradykinesia PLUS any of the following: r...
AB-1005 is an investigational small molecule being developed for the treatment of Parkinson's disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities. The drug is being studied in patients with moderate Parkinson's disease.
AB-1005 is being developed by Bayer AG, a pharmaceutical company traded on the OTC market under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Parkinson's disease.
AB-1005 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is designed to evaluate the drug in patients with moderate Parkinson's disease.
AB-1005 is being studied in a Phase 2 clinical trial with the identifier NCT07566429. The trial, titled 'A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)', is planned to enroll 8 participants in Japan and is not yet recruiting.
AB-1005 is described as a small molecule, but the clinical trial title refers to it as a gene therapy. The ongoing Phase 2 study is evaluating AB-1005 in Japanese adults with moderate Parkinson's disease. The drug is still in clinical development and not approved.